Aktuellt
SENASTE
Q4 is a reminder that Ascelia ticked some essential boxes during 2024, including completing a successful phase 3 study and securing growth capital for at least the entire 2025. Q4 is also a reminder that 2025 is about ensuring a timely FDA submission by mid-2025, promoting the phase 3 results and advancing ongoing conversations with potential partners ahead of the launch.
LÄS MER
